DOI: 10.1101/2023.06.06.23290973
Funding statement: This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024 Task Order No. 75N91022F00007 and for EMMES LLC under Division of Microbiology and Infectious Diseases contract # 75N93021C00012. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
− ARB has received research support from NIH-NIAID, grants from Pfizer, Cyanvac, and
Merck as well as consulting fees from Janssen and GSK.
− LRB has received grants from Wellcome Trust, Gates Foundation, NIH/Harvard Medical
School through institution. Serves as member of DSMB for NIH and AMDAC for FDA.
Dr Baden is involved in HIV and SARS-CoV-2 vaccine clinical trials conducted in
collaboration with the NIH, HIV Vaccine Trials Network (HVTN), Covid Vaccine
Prevention Network (CoVPN), International AIDS Vaccine Initiative (IAVI),
Crucell/Janssen, Moderna, Military HIV Research Program (MHRP), the Gates
Foundation, and Harvard Medical School.
− DJD has received a contract from Leidos Biomedical research to conduct the clinical trial
through institution.

− ARF has received grants from Janssen, Pfizer, Merck, BioFire Diagnostics, and
CyanVac through institution, consultant fees from Arrowhead and Icosavax, and
honoraria as a speaker from Moderna and GlaxoSmithKline. ARF also serves on
safety/advisory boards for Novavax and received travel/meeting support from
GlaxoSmithKline.
− SEF has received funding from Leidos to Saint Louis University to conduct Protocol
DMID22-0004.
− DNF has as a contract from CDC and is the site PI for clinical trials from Gilead,
Regeneron and MetroBiotech LLC. She is the PI on one investigator-initiated award from
Gilead and the co-PI on another investigator-initiated award from Gilead. DNF served on
an HBV Advisory board for Gilead in 2021 and received payment for expert testimony
not related to COVID in 2022.
− PAG has received funding for COVAIL clinical trial. PAG has also received consulting
fees from Janssen Vaccines.
− LCI has received support for the present manuscript from NIH-NIAID/DMID, Moderna,
Pfizer, and Sanofi. LCI has also received grants from GSK, Merck, Sharpe & Dohme
Corp, CDC, Novavax, AHRQ, and NIH/NLM/NIMHD as well as consulting fees from
Moderna, CDC, and Pediatric Emergency Medicine Associates, LLC. LCI has received
honoraria as a speaker from American Academy of Pediatrics, Rockefeller University,
and American Academy of Pediatrics- Georgia Chapter. LCI Serves on Data Safety
Monitoring for NIH-Phase 2 Vaccine Trial for Monkeypox, Moderna Scientific Advisory
Board- North America, and CoVID-19 Task Force, Georgia. LCI has a leadership role in
the Pediatric Infectious Disease Society and serves as board member on the Emory
University- Pediatric and Reproductive Environmental Health Scholars-Southeastern, the
Center for Spatial Analytics of the Georgia Institute of Technology, and the American
Academy of Pediatrics (Executive Board for Section on Infectious Diseases). LCI has
received travel/meeting support from the American Academy of Pediatrics and Moderna.
− LAJ has received funding from NIH for support for this study, funding from Pfizer to
support a clinical trial and contract funding for research support from the CDC and the
NIH, all through institution. LAJ also reports unpaid participation on Data Safety
Monitoring Boards for NIH funded clinical trials.
− SJL has received NIH grants through institution.
− AFL has received grants from Merck, Gilead and, Viiv through institution as well as
consulting fees from Vir Biotechnology. AFL has also received travel support from Merck

to attend a required investigator meeting, testing kits and supplies to support research
study from Hologic, and medication donated by Mayne Pharma to support research
study.
− MM has received funding from Division of Microbiology and Infectious Diseases for
contract # 75N93021C00012.

− DCM has received funding from NIH/75N93019C00050-21A: CIVICS A- Option 21A-
DMID Trials of COVID-19 Vaccines.

− JM has received funding from Division of Microbiology and Infectious Diseases, contract
# 75N93021C00012.
− AN has received support from NIH-NIAID, CEIRR (Centers of Excellence for Influenza
Research and Response) and Gates Cambridge Trust as well as grants from NIH-NIAID
R01.
− RMN has received grants from Moderna and Janssen and travel/meeting support from
Moderna.
− CMP has received funding from NIAID UM1AI148684.
− RMP has received funding from NIH DMID COVAIL as well as grants from Janssen,
Moderna and NIH through institution.
− NGR has received research grants from Pfizer, Merck, Sanofi, Quidel and Lilly through
institution, consulting fees from Krog, honoraria as speaker for Virology education, and
travel support from Sanofi. NGR serves on safety committees for ICON and EMMES and
is a member of the Moderna Advisory board.
− DJS has received support from NIH-NIAID CEIRR , grants from NIH-NIAID R01, and
travel support from NIH-NIAID CEIRR for NIH-related meetings.
− KT has received funding from Division of Microbiology and Infectious Diseases contract
# 75N93021C00012.
− EBW has received funding from Leidos Biomedical Research AGREEMENT NO.
22CTA-DM0009 as well as grants from Pfizer, Moderna, Sequiris, Clinetic, and Najit
Technologies, with payments made to institution. EBW has also received honoraria as a
speaker from College of Diplomates of the American Board of Pediatric Dentistry,
consulting fees from Iliad Biotechnologies, and travel/meeting support from the American
Academy of Pediatrics. EBW serves as member of Vaxcyte Scientific Advisory board.
− PLW has received subcontract funding from NIH for this study as well as NIH grant
funding and contract funding from Pfizer through University of Iowa. PLW has also

received consulting fees from Pfizer and serves on safety/advisory board for Emmes
Corporation.
− SK has received research grants from Pfizer.
Annotated funders:
funder_name: National Cancer Institute, National Institutes of Health
awards: award_ids: 75N91019D00024
75N91022F00007
funder_name: EMMES LLC
awards: award_ids: 75N93021C00012
funder_name: Division of Microbiology and Infectious Diseases
awards: award_ids: 75N93021C00012
funder_name: NIH-NIAID
awards: award_ids: UM1AI148684
R01
funder_name: Pfizer
funder_name: Cyanvac
funder_name: Merck
funder_name: Janssen
funder_name: GSK
funder_name: Wellcome Trust
funder_name: Gates Foundation
funder_name: Harvard Medical School
funder_name: NIH
awards: award_ids: 75N93019C00050-21A
funder_name: Leidos Biomedical research
awards: award_ids: 22CTA-DM0009
funder_name: BioFire Diagnostics
funder_name: Arrowhead
funder_name: Icosavax
funder_name: Moderna
funder_name: Novavax
funder_name: GlaxoSmithKline
funder_name: Saint Louis University
awards: award_ids: DMID22-0004
funder_name: CDC
funder_name: Gilead
funder_name: Regeneron
awards: award_title: investigator-initiated award
funder_name: Janssen Vaccines
funder_name: MetroBiotech LLC
funder_name: AHRQ
funder_name: NIH/NLM/NIMHD
funder_name: Sanofi
funder_name: Sharpe & Dohme
Corp
funder_name: Pediatric Emergency Medicine Associates, LLC
funder_name: American Academy of Pediatrics
funder_name: Rockefeller University
funder_name: Georgia Institute of Technology
funder_name: Viiv
funder_name: Vir Biotechnology
funder_name: Hologic
funder_name: Mayne Pharma
funder_name: CEIRR (Centers of Excellence for Influenza Research and Response)
funder_name: Gates Cambridge Trust
funder_name: Quidel
funder_name: Lilly
funder_name: Krog
funder_name: Virology education
funder_name: ICON
funder_name: Clinetic
funder_name: Najit Technologies
funder_name: Iliad Biotechnologies
funder_name: Vaxcyte
funder_name: Emmes Corporation